Enovis Corporation (NYSE:ENOV) is included in our list of the 14 oversold value stocks to invest in right now.
Pixabay/Public domain
Enovis Corporation (NYSE:ENOV) underwent a challenging period in 2025 amid macro headwinds. With the stock down 50% over the past year, the shares ended-up hitting their 52-week low on January 29, 2026, closing at $21.00.
Amid weak investor momentum, Enovis Corporation (NYSE:ENOV) drew attention from Evercore ISI analyst Vijay Kumar on January 12, who reiterated the firm’s ‘Outperform’ rating with a $40 price target. The firm’s update came in response to the company’s Q4 pre-announcement.
Evercore ISI shed light on the company’s revenue miss, roughly 3% below analyst expectations. However, the firm acknowledged the positive angle, highlighting the implied 11% EPS beat driven by higher-margin reconstructive operations. The firm remains bullish, projecting that FY26 cash flow will improve, with free cash flow conversion exceeding 25% in the fourth quarter.
Furthermore, on January 6, 2026, Enovis Corporation (NYSE:ENOV) saw BTIG analyst Ryan Zimmerman initiate coverage on the stock with a ‘Buy’ rating and a $41 price target. The firm’s bullish stance reflects ENOV’s multi-segment orthopedic strategy and ability to outperform end markets. Right now, the firm sees an attractive entry point for investors despite concerns surrounding scale, tariffs, and cash flow.
Enovis Corporation (NYSE:ENOV) develops clinically differentiated orthopedic solutions across the Prevention & Recovery and Reconstructive segments.
While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.
Disclosure: None.
